(berahyaluronidase alfa + pembrolizumab)

all catalysts(5)

News(3)

• Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
  Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.
  biopharma_dive · 5d ago
• Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
  The anti-TL1A antibody from Merck's 2023 Prometheus buy delivered positive mid-stage results in a skin condition but failed in a certain type of lung disease, the Big Pharma revealed alongside seco…
  biospace · 6d ago
• Medicare drug price rule may target under-the-skin Keytruda and Opdivo
  For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.
  biopharma_dive · 1mo ago